196 related articles for article (PubMed ID: 38068712)
21. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
[TBL] [Abstract][Full Text] [Related]
22. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
23. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
Shu C; Li Q
Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells.
Tufano M; D'Arrigo P; D'Agostino M; Giordano C; Marrone L; Cesaro E; Romano MF; Romano S
Cells; 2021 Sep; 10(9):. PubMed ID: 34572014
[TBL] [Abstract][Full Text] [Related]
25. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
26. Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion.
Wang S; Park SH; Lim JS; Park YY; Du L; Lee JH
Genes Genomics; 2022 Dec; 44(12):1509-1517. PubMed ID: 35917090
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset.
Wang H; Xiao Y; Ren X; Wan D
Bioengineered; 2021 Dec; 12(2):10366-10378. PubMed ID: 34903133
[TBL] [Abstract][Full Text] [Related]
28. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
[TBL] [Abstract][Full Text] [Related]
29. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
[TBL] [Abstract][Full Text] [Related]
31. TNF-α-dependent lung inflammation upregulates PD-L1 in monocyte-derived macrophages to contribute to lung tumorigenesis.
Wen Y; Wang X; Meng W; Guo W; Duan C; Cao J; Kang L; Guo N; Lin Q; Lv P; Zhang R; Xing L; Zhang X; Shen H
FASEB J; 2022 Nov; 36(11):e22595. PubMed ID: 36205325
[TBL] [Abstract][Full Text] [Related]
32. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
Front Immunol; 2021; 12():637053. PubMed ID: 34108959
[TBL] [Abstract][Full Text] [Related]
33. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
[TBL] [Abstract][Full Text] [Related]
34. Exosomal L1CAM Stimulates Glioblastoma Cell Motility, Proliferation, and Invasiveness.
Pace KR; Dutt R; Galileo DS
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426278
[TBL] [Abstract][Full Text] [Related]
35. Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme-a retrospective cohort study.
Masood AB; Batool S; Bhatti SN; Ali A; Valko M; Jomova K; Kuca K
Front Immunol; 2023; 14():1202098. PubMed ID: 37529045
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
37. The ellagic acid metabolites urolithin A and B differentially affect growth, adhesion, motility, and invasion of endometriotic cells in vitro.
Mc Cormack B; Maenhoudt N; Fincke V; Stejskalova A; Greve B; Kiesel L; Meresman GF; Vankelecom H; Götte M; Barañao RI
Hum Reprod; 2021 May; 36(6):1501-1519. PubMed ID: 33748857
[TBL] [Abstract][Full Text] [Related]
38. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
39. Role of human gut microbiota metabolism in the anti-inflammatory effect of traditionally used ellagitannin-rich plant materials.
Piwowarski JP; Granica S; Zwierzyńska M; Stefańska J; Schopohl P; Melzig MF; Kiss AK
J Ethnopharmacol; 2014 Aug; 155(1):801-9. PubMed ID: 24969824
[TBL] [Abstract][Full Text] [Related]
40. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
